What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Myocardial infarction
John W. Eikelboom mostly deals with Internal medicine, Stroke, Surgery, Anesthesia and Warfarin.
John W. Eikelboom regularly ties together related areas like Cardiology in his Internal medicine studies.
His Stroke research is multidisciplinary, incorporating elements of Embolism, Anticoagulant, Proportional hazards model, Atrial fibrillation and Apixaban.
As a part of the same scientific study, John W. Eikelboom usually deals with the Anticoagulant, concentrating on Intensive care medicine and frequently concerns with Heparin.
His Anesthesia research is multidisciplinary, relying on both Platelet aggregation inhibitor, Vascular surgery and Randomized controlled trial.
John W. Eikelboom studies Dabigatran which is a part of Warfarin.
His most cited work include:
- Dabigatran versus warfarin in patients with atrial fibrillation (7970 citations)
- Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium (2146 citations)
- Apixaban in Patients with Atrial Fibrillation (1891 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Cardiology, Stroke, Atrial fibrillation and Surgery.
His study in the field of Aspirin, Myocardial infarction, Randomized controlled trial and Rivaroxaban is also linked to topics like In patient.
His Stroke study incorporates themes from Homocysteine, Vascular disease, Embolism and Risk factor.
In his study, which falls under the umbrella issue of Atrial fibrillation, Antithrombotic is strongly linked to Intensive care medicine.
His biological study focuses on Dabigatran.
John W. Eikelboom has researched Dabigatran in several fields, including Anticoagulant, Anesthesia and Renal function.
He most often published in these fields:
- Internal medicine (66.83%)
- Cardiology (35.83%)
- Stroke (34.50%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (66.83%)
- Aspirin (24.00%)
- Rivaroxaban (17.97%)
In recent papers he was focusing on the following fields of study:
John W. Eikelboom spends much of his time researching Internal medicine, Aspirin, Rivaroxaban, Stroke and Atrial fibrillation.
His Myocardial infarction, Coronary artery disease and Randomized controlled trial study in the realm of Internal medicine connects with subjects such as In patient.
His research in Randomized controlled trial focuses on subjects like Placebo, which are connected to Anesthesia.
His Aspirin study integrates concerns from other disciplines, such as Hazard ratio, Disease, Randomization and Antithrombotic.
His Antithrombotic research integrates issues from Clopidogrel, Clinical trial and Intensive care medicine.
John W. Eikelboom has included themes like MEDLINE and Confidence interval in his Stroke study.
Between 2017 and 2021, his most popular works were:
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up (1132 citations)
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up (1132 citations)
- Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors (288 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Disease
His primary areas of investigation include Internal medicine, Aspirin, Rivaroxaban, Cardiology and In patient.
Internal medicine is represented through his Coronary artery disease, Randomized controlled trial, Hazard ratio, Stroke and Atrial fibrillation research.
As a part of the same scientific family, John W. Eikelboom mostly works in the field of Stroke, focusing on Physical therapy and, on occasion, Stent.
His research on Atrial fibrillation focuses in particular on Warfarin.
He combines subjects such as Clinical trial, Conventional PCI, Myocardial infarction, Antithrombotic and Secondary prevention with his study of Aspirin.
His biological study spans a wide range of topics, including Surgery and Dabigatran, Edoxaban.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
